Cardiovascular DiseasesNCT00005383
Anger and Cardiovascular Risk in Urban Youth
An observational study of Cardiovascular Diseases and Heart Diseases, run by National Heart, Lung, and Blood Institute (NHLBI).
Trial summary
To examine anger and cardiovascular disease risk in urban youth. The project studied patterns of hemodynamic responses to social and nonsocial stressors, ambulatory blood pressure (BP), fasting insulin, fasting glucose, lipid profiles, and central obesity in adolescents from a wide range of socioeconomic status (SES)… Read more about this study
- Who is it for?
- Ages Up to 100 years, men only
- Conditions the study is for
- Cardiovascular Diseases, Heart Diseases, Hypertension
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Jan 1995to Dec 1999
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 100 years
- Men only
- No healthy volunteers
- Child, Adult, Older adult
About this study
To examine anger and cardiovascular disease risk in urban youth. The project studied patterns of hemodynamic responses to social and nonsocial stressors, ambulatory blood pressure (BP), fasting insulin, fasting glucose, lipid profiles, and central obesity in adolescents from a wide range of socioeconomic status (SES) backgrounds.
Read the detailed description
BACKGROUND:
Urban adolescents at high risk for cardiovascular disease (CVD) exhibit a pattern of hemodynamic responses that: (a) is evoked by social encounters that arouse anger, defensiveness, and distrust; (b) appears related to increased insulin resistance; (c) is more pronounced in males and African Americans; and (d) may constitute a pathway via which chronic exposure to stressful social environments increases CVD risk.
DESIGN NARRATIVE:
There were four studies. Study 1 in the first two years measured hemodynamics in 200 subjects to test the hypothesis that hostile distrust was associated with increased total peripheral resistance (TPR) response to social challenge, and that adolescents exhibiting this response pattern had elevated levels of ambulatory BP, fasting insulin, glucose, blood lipids, and central obesity. Study 2 followed 200 subjects for four years to determine if defensive hostility and distrust were related to tracking at higher levels of BP (measured every 6 months), and insulin/ glucose/ cholesterol (measured once per year). Study 3 in years 3 and 4 evaluated the influence of race on the cross-situational consistency of hostile distrust/BP by measuring the latter responses in 200 adolescents during structured encounters with a friend of the same race and sex, an unfamiliar same-race peer, and an unfamiliar other-race peer (black or white). Study 4 evaluated video and audiotape recordings from Studies 1 and 3 to test the hypothesis that distrustful individuals expressed more hostile affect in encounters with others, elicited more negative treatment, were perceived as hostile regardless of observer race or gender, and thus experienced chronic, health-damaging interpersonal stress. Study 4 data were used to examine the possibility that hostile distrust is related to exposure to crime, poverty, and racial discrimination.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Hypertension, Obesity
- Medical subject headings
- Cardiovascular Diseases, Heart Diseases, Hypertension, Obesity
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2000 (estimated)
- Study startJan 1995
- Study completionDec 1999
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- More trials run by National Heart, Lung, and Blood Institute (NHLBI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00005383
- Sponsor's protocol ID
- 4288
- Other IDs
- R01HL052080
- Status last verified
- Sep 2002
- First submitted
- 25 May 2000
- Last updated
- 18 Feb 2016
- Results posted
- No
Publications
Ewart CK, Jorgensen RS, Kolodner KB. Sociotropic cognition moderates blood pressure response to interpersonal stress in high-risk adolescent girls. Int J Psychophysiol. 1998 Mar;28(2):131-42. doi: 10.1016/s0167-8760(97)00091-3.
PubMed 9545651Ewart CK, Suchday S. Discovering how urban poverty and violence affect health: development and validation of a Neighborhood Stress Index. Health Psychol. 2002 May;21(3):254-62. doi: 10.1037//0278-6133.21.3.254.
PubMed 12027031
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Anger and Cardiovascular Risk in Urban Youth
- ClinicalTrials.gov ID
- NCT00005383
- Acronym / sponsor ID
- 4288
- Conditions
- Cardiovascular Diseases, Heart Diseases, Hypertension, Obesity
- Study type
- Observational
- Recruitment status
- Completed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)US National Institutes of Health
- Study start
- Jan 1995
- Study completion
- Dec 1999 (actual)
- First posted
- 26 May 2000 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To examine anger and cardiovascular disease risk in urban youth. The project studied patterns of hemodynamic responses to social and nonsocial stressors, ambulatory blood pressure (BP), fasting insulin, fasting glucose, lipid profiles, and central obesity in adolescents from a wide range of socioeconomic status (SES) backgrounds.
Detailed description
BACKGROUND:
Urban adolescents at high risk for cardiovascular disease (CVD) exhibit a pattern of hemodynamic responses that: (a) is evoked by social encounters that arouse anger, defensiveness, and distrust; (b) appears related to increased insulin resistance; (c) is more pronounced in males and African Americans; and (d) may constitute a pathway via which chronic exposure to stressful social environments increases CVD risk.
DESIGN NARRATIVE:
There were four studies. Study 1 in the first two years measured hemodynamics in 200 subjects to test the hypothesis that hostile distrust was associated with increased total peripheral resistance (TPR) response to social challenge, and that adolescents exhibiting this response pattern had elevated levels of ambulatory BP, fasting insulin, glucose, blood lipids, and central obesity. Study 2 followed 200 subjects for four years to determine if defensive hostility and distrust were related to tracking at higher levels of BP (measured every 6 months), and insulin/ glucose/ cholesterol (measured once per year). Study 3 in years 3 and 4 evaluated the influence of race on the cross-situational consistency of hostile distrust/BP by measuring the latter responses in 200 adolescents during structured encounters with a friend of the same race and sex, an unfamiliar same-race peer, and an unfamiliar other-race peer (black or white). Study 4 evaluated video and audiotape recordings from Studies 1 and 3 to test the hypothesis that distrustful individuals expressed more hostile affect in encounters with others, elicited more negative treatment, were perceived as hostile regardless of observer race or gender, and thus experienced chronic, health-damaging interpersonal stress. Study 4 data were used to examine the possibility that hostile distrust is related to exposure to crime, poverty, and racial discrimination.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
Study design
Who may qualify
- Ages
- Up to 100 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2016.
- Background: PubMed 9545651Ewart CK, Jorgensen RS, Kolodner KB. Sociotropic cognition moderates blood pressure response to interpersonal stress in high-risk adolescent girls. Int J Psychophysiol. 1998 Mar;28(2):131-42. doi: 10.1016/s0167-8760(97)00091-3.
- Background: PubMed 12027031Ewart CK, Suchday S. Discovering how urban poverty and violence affect health: development and validation of a Neighborhood Stress Index. Health Psychol. 2002 May;21(3):254-62. doi: 10.1037//0278-6133.21.3.254.
Related trials for Cardiovascular Diseases
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Diseases and Heart Diseases, run by National Heart, Lung, and Blood Institute (NHLBI).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00005383, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2016.